vTv Therapeutics (Nasdaq: VTVT) granted 2,500 stock options to a non-executive employee as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $31.48 per share, a 10-year term, and vest over four years, with 25% vesting after one year and the remainder vesting quarterly over the next 36 months, subject to continued employment.
The grant is made under the company’s 2026 Inducement Plan. vTv is a late-stage biopharmaceutical company whose clinical pipeline is led by cadisegliatin (TTP399), an oral glucokinase activator in a US Phase 3 trial for type 1 diabetes and granted FDA Breakthrough Therapy designation.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
The comparable grant history included news_id 1065944 with a -0.18% 24-hour move. Against that recor...
Analysis
The comparable grant history included news_id 1065944 with a -0.18% 24-hour move. Against that record, the current award is best read alongside the active S-3 shelf and low short positioning; dilution and trial execution remain risks.
Key Figures
Stock Options:2,500 optionsExercise Price:$31.48 per shareInitial Vesting:25%+4 more
7 metrics
Stock Options2,500 optionsInducement grant to a non-executive employee
Exercise Price$31.48 per shareExercise price for the granted options
Initial Vesting25%Vests on the one-year anniversary
Vesting Period4 yearsTotal vesting period for the option award
Remaining Vesting36 monthsQuarterly vesting after the first anniversary
Option Term10 yearsTerm of the granted options
Trial PhasePhase 3Cadisegliatin trial in type 1 diabetes
"as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
glucokinase activatormedical
"a potential first-in-class oral glucokinase activator being investigated"
A glucokinase activator is a drug that boosts the activity of glucokinase, an enzyme that helps the liver and pancreas sense and lower blood sugar. Think of it as turning up the sensitivity of the body’s sugar thermostat so insulin release and sugar storage respond more effectively; for investors, these drugs matter because they can become new diabetes treatments with sizable market potential while carrying typical development, safety and regulatory risks that affect a company’s value.
breakthrough therapy designationregulatory
"Cadisegliatin has been granted Breakthrough Therapy designation"
A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.
adjunctive therapymedical
"a novel, potential first-in-class oral adjunctive therapy to insulin"
Adjunctive therapy is a treatment given in addition to a primary therapy to boost its effectiveness, reduce side effects, or treat related symptoms — like adding a side dish to make a main meal work better. For investors, evidence that an adjunctive therapy improves outcomes, safety, or convenience can expand a product’s use, support stronger regulatory labeling and reimbursement, and increase commercial potential by reaching more patients or strengthening a therapy’s market position.
HIGH POINT, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 2,500 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options that were granted at an exercise price of $31.48 per share.Each option award will vest over a 4-year period, with 25% of the shares underlying the option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting quarterly over the following 36 months, subject to continued employment with vTv on such vesting dates.The options have a term of 10 years and are subject to the terms and conditions of the 2026 Inducement Plan and the stock option agreement covering the grant.
AboutvTvTherapeutics vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a US Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.
About Cadisegliatin Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the US as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin acted selectively on the liver and increased the activity of glucokinase independently from insulin. These studies support clinical investigation of whether cadisegliatin can improve glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).
Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.
What inducement stock options did vTv Therapeutics (VTVT) grant on August 19, 2026?
vTv Therapeutics granted 2,500 inducement stock options to a non-executive employee on August 19, 2026. According to vTv Therapeutics, the options have a $31.48 exercise price, 10-year term, and four-year vesting schedule, with 25% after one year and the rest vesting quarterly.
How do the vTv Therapeutics (VTVT) inducement options under Nasdaq Rule 5635(c)(4) vest?
The vTv Therapeutics inducement options vest over four years under Nasdaq Rule 5635(c)(4). According to vTv Therapeutics, 25% vests on the one-year anniversary of the vesting commencement date, and the remaining shares vest quarterly over the following 36 months, subject to continued employment.
What is the exercise price and term of the vTv Therapeutics (VTVT) August 2026 inducement options?
The inducement options have an exercise price of $31.48 per share and a 10-year term. According to vTv Therapeutics, these options were granted under the 2026 Inducement Plan as a material inducement to employment for a non-executive employee.
What is cadisegliatin (TTP399) in vTv Therapeutics’ (VTVT) pipeline?
Cadisegliatin (TTP399) is an oral, liver-selective glucokinase activator in a US Phase 3 trial. According to vTv Therapeutics, it is being investigated as a potential first-in-class oral adjunctive treatment for type 1 diabetes and has FDA Breakthrough Therapy designation.
Has cadisegliatin from vTv Therapeutics (VTVT) been proven safe and effective or received FDA approval?
Cadisegliatin has not yet been proven safe and effective or received FDA approval. According to vTv Therapeutics, it remains under investigation, and there is no guarantee it will obtain health authority approval or become commercially available for the use being studied.
